

***Fiscal Year 2020 Autism Research Program
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
<p>Clinical Trial Award Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-20-ARP-CTA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p> <p><i>or</i></p> <p>Early-Career Investigator Partnering Principal Investigator (PI) Option: Investigators at or above the level of Assistant Professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) that meets the following criteria at the application submission deadline date:</p> <ul style="list-style-type: none"> • Must be in a current postdoctoral training position or have completed postdoctoral training by the application deadline • Is no more than 7 years from the receipt of a terminal degree • Has the freedom to commit at least 50% time to the project 	<ul style="list-style-type: none"> • Supports research with the potential to have a major impact on the treatment and/or management of autism spectrum disorder (ASD). • Applications in the following areas are strongly encouraged: <ul style="list-style-type: none"> ○ Dissemination/implementation of clinically validated interventions ○ Behavioral, cognitive, and other non-pharmacological therapies for ASD core symptoms or to alleviate co-occurring conditions ○ Pharmacological, genetic, and other biological treatments for ASD core symptoms or to alleviate co-occurring conditions ○ Improve diagnosis and access to services across the life span ○ Interventions promoting success in key transitions to adulthood for individuals living with ASD ○ Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief) ○ Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services ○ Understanding heterogeneity in treatment response • Preliminary data relevant to the proposed project are required. • Early-Career Investigator Partnering PI Option supports the development of young investigators pursuing or wishing to pursue a career in ASD clinical trial research. • Pre-application is required; application submission is by invitation only. 	<ul style="list-style-type: none"> • The maximum period of performance is 4 years. • The maximum allowable funding for the entire period of performance is \$2,000,000 in direct costs (plus indirect costs). <p>Early-Career Investigator Partnering PI Option:</p> <ul style="list-style-type: none"> • The maximum period of performance is 4 years. • The maximum allowable funding for the entire period of performance is \$2,300,000 for direct costs (plus indirect costs). 	<p>Pre-Application: April 28, 2020 5:00 p.m. Eastern time (ET)</p> <p>Invitation to Submit an Application: June 2020</p> <p>Application: July 28, 2020 11:59 p.m. ET</p>

***Fiscal Year 2020 Autism Research Program
Reference Table of Award Mechanisms and Submission Requirements***

<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p><u>W81XWH-20-ARP-IDA</u></p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p> <p><i>or</i></p> <p>Multiple PI Option: Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.</p>	<ul style="list-style-type: none"> • Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes. • Applications in the following areas are strongly encouraged: <ul style="list-style-type: none"> ○ Tests of implementation strategies to increase use of evidence-based practices ○ Development of healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief) ○ Assessment of novel therapeutics using valid preclinical models ○ Mechanisms of heterogeneous clinical expression of ASD ○ Environmental risk factors ○ Improve diagnosis across the life span ○ Factors promoting success in key transitions to independence for individuals living with ASD ○ Cultural and socioeconomic factors in treatment efficacy, delivery, and access to services ○ Mechanisms underlying sex differences in ASD diagnosis ○ Mechanisms underlying conditions co-occurring with ASD (e.g., sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, seizures) ○ Factors impacting quality of life during geographic relocation, such as military permanent change of station ○ Long-term treatment outcomes from previous clinical trials for ASD core symptoms or to alleviate co-occurring conditions • Preliminary data are required. • Multiple PI Option: Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award. • Pre-application is required; application submission is by invitation only. 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$550,000 in direct costs (plus indirect costs). • For multiple PIs, the combined funding for all PIs for the entire period of performance may not exceed \$550,000 in direct costs (plus indirect costs). 	<p>Pre-Application: April 28, 2020 5:00 p.m. ET</p> <p>Invitation to Submit an Application: June 2020</p> <p>Application: July 28, 2020 11:59 p.m. ET</p>
--	---	--	---	--

***Fiscal Year 2020 Autism Research Program
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
<p>Clinical Translational Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p><u>W81XWH-20-ARP-CTRA</u></p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Supports early-phase, proof-of-principle translational studies with the potential to have a major impact on the treatment and/or management of ASD. • Applications in the following areas are strongly encouraged: <ul style="list-style-type: none"> ○ Dissemination/implementation of clinically validated interventions ○ Behavioral, cognitive, and other non-pharmacological therapies for ASD core symptoms or to alleviate co-occurring conditions ○ Pharmacological, genetic, and other biological treatments for ASD core symptoms or to alleviate co-occurring conditions ○ Improve diagnosis and access to services across the life span ○ Interventions promoting success in key transitions to adulthood for individuals living with ASD ○ Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief) ○ Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services ○ Understanding heterogeneity in treatment response • Preliminary data relevant to the proposed project are <i>required</i>. • <i>Pre-application is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$600,000 in direct costs (plus indirect costs). 	<p>Pre-Application: April 28, 2020 5:00 p.m. ET</p> <p>Invitation to Submit an Application: June 2020</p> <p>Application: July 28, 2020 11:59 p.m. ET</p>